ENU Medicines
June 22, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Immunology
We’re developing first-in-class oral therapeutics for food allergy, based on forward genetic discoveries that identify disease-driving targets in vivo.
Company HQ City:
Palo Alto
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2025
CEO
Jerry Chen
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}